Elvin Wagenblast

Elvin Wagenblast is a researcher at the Icahn School of Medicine at Mount Sinai, affiliated with the Graduate School of Biomedical Sciences and key institutes including the Tisch Cancer Institute, Black Family Stem Cell Institute, and Center for Advancement of Blood Cancer Therapies. His work focuses on hematopoietic stem cells and leukemogenesis.

• PhD in Blood Cancer Therapies
• Active in oncological sciences and cancer mechanisms

Research Interests:
Elvin's research delves into acute myeloid leukemia (AML), leukemic stem cells, and hematopoietic cell regulation, with emphasis on overcoming therapy resistance, lysosomal targeting, and immunogenic responses in T-lineage leukemias.

Scientific Contributions:
His recent work (2025) highlights inflammatory biomarkers in ALL, cholesterol metabolism in dendritic cell regulation, and FLT3 dependency in mutated leukemic stem cells. These studies align with precision medicine approaches.

• Published in Science Translational Medicine (2025)
• Key findings in Nature Immunology (2025) on immunological responses
• Advancing AML therapies via Blood (2025)

Scientific Recognition:
Awarded by the Leukemia & Lymphoma Society (2024) for childhood leukemia research. Collaborative work (2025) with the AACR NextGen Stars further established his role in cancer innovation.

Labs & Collaborations:
Works within the Center for Advancement of Blood Cancer Therapies, focusing on stem cell dynamics and drug resistance. Collaborates with international teams in hematology and immunology networks.